Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 214Neoplasms 197Carcinoma, Non-Small-Cell Lung 91Colorectal Neoplasms 89Prostatic Neoplasms 78Lung Neoplasms 75Multiple Myeloma 49Head and Neck Neoplasms 47Melanoma 46Pancreatic Neoplasms 45Neoplasm Metastasis 44Leukemia, Myeloid, Acute 41Carcinoma, Hepatocellular 41Recurrence 37Brain Neoplasms 37Squamous Cell Carcinoma of Head and Neck 34Ovarian Neoplasms 32Glioblastoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Glioma 29Uterine Cervical Neoplasms 27Sarcoma 27Stomach Neoplasms 26Lymphoma, Non-Hodgkin 26Lymphoma 26Carcinoma, Renal Cell 26Motor Activity 24Lymphoma, Follicular 24Colonic Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22

Interventions

dalpiciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × HR+/HER2- Advanced Breast Cancer × 90 days × Clear all
NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Completed
22 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡